GlassScriptPhysician profile
Carlos M Castillo
NPI 1922095884
$4,655.90
in general payments reported to CMS, 2019-2025
39 companies · $452 in 2025
The $452 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,423 · 2020: $520 · 2021: $738 · 2022: $253 · 2023: $240 · 2024: $28.31 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677 · Education: $43.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.10 |
| Education | $43.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $500.23 | 2019-2025 | Talvey, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $478.26 | 2019-2022 | |
| Daiichi Sankyo INC. | $325.42 | 2019-2020 | |
| Amgen INC. | $288.27 | 2019-2025 | Imdelltra (Amg757), Kyprolis |
| Genentech USA, INC. | $236.84 | 2019-2023 | Venclexta |
| Astrazeneca Pharmaceuticals LP | $231.47 | 2019 | |
| Incyte Corporation | $198.95 | 2021-2022 | |
| Eisai INC. | $191.34 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $188.18 | 2019-2022 | |
| Pfizer INC. | $170.34 | 2019-2021 | |
| Seagen INC. | $169.71 | 2020-2021 | |
| Verastem, INC. | $141.14 | 2019 | |
| Glaxosmithkline, LLC. | $138.70 | 2020-2025 | Jemperli |
| Ucb, INC. | $130.91 | 2021 | |
| Pharmacosmos Therapeutics INC. | $114.09 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.